HomeCONGRESS

CONGRESS

View Category
Day 1

PRAMI: Treating other lesions in addition to the culprit of an acute infarction reduces events.

In the context of an ST-segment elevation myocardial infarction, primary angioplasty to treat the culprit lesion improves...
solaci -
Learn More
Day 1

TAO trial: Otamixaban without advantages as the only anticoagulant in acute coronary syndromes

Despite progress in antiplatelet, anticoagulant therapy and invasive strategy, patients with non-ST-segment elevation acute coronary syndrome present...
solaci -
Learn More
Day 1

TASTE: Thrombus aspiration in primary angioplasty failed to show benefits at 30 days

The clinical benefit of thrombus aspiration during angioplasty in patients with ST-segment elevation myocardial infarction is uncertain....
solaci -
Learn More
Day 1

RE-ALIGN: Dabigatran in mechanical valves. Suspended early due to more bleeding and thrombotic events.

The use of vitamin K antagonists provides excellent protection against thromboembolic complications in patients with mechanical valves,...
solaci -
Learn More
Day 1

Hokusai-VTE: Endoxaban shows solid results versus warfarin in venous thromboembolism .

The venous thromboembolism is the third most common cardiovascular disease after acute myocardial infarction and stroke ....
solaci -
Learn More
Day 1

ACCOAST: Pretreatment with prasugrel showed no benefits and increased bleeding in patients with non-ST segment myocardial infarction.

This study evaluated the administration of prasugrel at the time of diagnosis of non-ST segment acute coronary...
solaci -
Learn More
Day 3

ATOMIC: Omecamtiv Mecarbil does not relieve dyspnea in patients with heart failure

This is a phase 2 randomized, double-blind controlled study to test the effect of omecamtiv mecarbil on...
solaci -
Learn More
Day 2

PURE: Cardiovascular disease contrast between developed and undeveloped countries.

80% of the global burden of cardiovascular disease is located in countries with low or middle incomes....
solaci -
Learn More